

Zydus receives tentative approval from the USFDA for Lorcaserin Hydrochloride Tablets

Ahmedabad, 3 December 2019

Zydus Cadila has received the tentative approval from the USFDA to market Lorcaserin Hydrochloride Tablets (US RLD – Belviq Tablets), 10 mg. The drug is used together with diet and exercise to treat obesity. It will be manufactured at the group's formulations manufacturing facility at SEZ.

The group now has 278 approvals and has so far filed over 330 ANDAs since the commencement of the filing process in FY 2003-04.

About Zydus Cadila

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. The group employs nearly 25,000 people worldwide and is dedicated to creating healthier communities globally. Zydus aspires to be a research-based pharmaceutical company by 2020.
